Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The Triumph clinical trial

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Oct 14, 2024 9:10pm

56 Views

Post# 36265736

RE:The Triumph clinical trial

Why is it always people with HIV. Why not just anybody?

scarlet1967 wrote:
ClinicalTrials.gov

ClinicalTrials.gov

"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.

This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations."

All the weight loss drugs(annual sales of 6 billion dollars in 2023 and as per Morgan Stanley the projected sales by 2030 is well above 100 billions)can result in muscle loss which can be a problem in the long run specially for older people. This clinical trial scheduled to start early 2025 by Dr. Lindsay Fourman (who has been involved in many studies of the drug) will be evaluating the effects of Tesamorelin on "physical performance and muscle strength" among aging HIV patients "with potential applications to other patient populations".

The point is these extremely popular weight loss drugs need to be taken continuously and the side effects such as fatigue need to be dealt with in order to keep the patient on them so this is a potentially significant commercial opportunity for Tesamorelin.